ARCHIVES

NCI Staff Will Recommend That Comprehensive Recognition Be Withdrawn From Colorado Center

This article is from The Cancer Letter archive.

Vol. 06 No. 43 | October 31, 1980

Download PDF Visit The Full Archive

Related Articles

FDA Committee Okays Leuprolide NDA, But Recommends Against Mitoxantrne, Epirubicin

April 5, 1985

Phase III Xtandi Trial Meets Primary Endpoints Of Progression-Free and Overall Survival

November 29, 2013

EntreMed Begins Phase I/II Trial For Endostatin.

July 27, 2001

$20 Million In Construction Funds Approved

April 2, 1976

Guest Editorial: Andrew Vickers on PSA Skepticism, Rational and Irrational

October 10, 2014

White House Backs Down FY 86 Cuts, Says Now They Will Be Limited To Trimming Indirect Costs

January 10, 1986